following a full submission under the orphan medicine process:
zanubrutinib (Brukinsa®) is accepted for use within NHSScotland.
Indication Under Review: as monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
In a single-arm, open-label, phase II study, zanubrutinib monotherapy resulted in an overall response rate of 68% in patients with MZL who had received at least one prior anti-CD20-based therapy.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- zanubrutinib (Brukinsa)
- SMC ID:
- SMC2684
- Indication:
As monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
- Pharmaceutical company
- BeiGene UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 December 2024